AbbVie Licenses Nxera Gut Targeted EP4 Agonist

Previously missed November 4 transaction: Nxera Pharma licensed worldwide rights to its oral EP4 agonist NXE0033744 for inflammatory bowel disease to AbbVie. The agreement specifies $100 million upfront, up to $1.37 billion contingent milestones…




